|
UBXN2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.72980000007806E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.34319999997879E-06 |
| Normal-vs-Stage2 |
7.789800E-04 |
| Normal-vs-Stage3 |
1.22169999672295E-08 |
| Normal-vs-Stage4 |
5.52900000005963E-07 |
| Stage1-vs-Stage2 |
9.875800E-01 |
| Stage1-vs-Stage3 |
8.302300E-02 |
| Stage1-vs-Stage4 |
1.572380E-01 |
| Stage2-vs-Stage3 |
2.189400E-01 |
| Stage2-vs-Stage4 |
3.383600E-01 |
| Stage3-vs-Stage4 |
8.701200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.03649999483713E-08 |
| Normal-vs-AfricanAmerican |
2.198000E-02 |
| Normal-vs-Asian |
5.353300E-04 |
| Caucasian-vs-AfricanAmerican |
2.036600E-01 |
| Caucasian-vs-Asian |
3.197200E-01 |
| AfricanAmerican-vs-Asian |
6.075600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.37090000018603E-07 |
| Normal-vs-Female |
4.3191999998804E-07 |
| Male-vs-Female |
9.708400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.61200000000328E-05 |
| Normal-vs-Age(41-60Yrs) |
4.39209999480994E-08 |
| Normal-vs-Age(61-80Yrs) |
8.70589999979465E-07 |
| Normal-vs-Age(81-100Yrs) |
4.624600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.433000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.610200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.462230E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.169000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.913360E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.792960E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.596200E-02 |
| Classical-VS-Follicular |
1.857830E-01 |
| Classical-VS-Other |
3.048600E-01 |
| Classical-VS-Normal |
4.23869999999216E-06 |
| Tall-VS-Follicular |
4.831600E-01 |
| Tall-VS-Other |
7.916000E-01 |
| Tall-VS-Normal |
1.63424999999329E-05 |
| Follicular-VS-Other |
5.967400E-01 |
| Follicular-VS-Normal |
4.43480000000829E-06 |
| Other-VS-Normal |
9.063500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.97500000020945E-07 |
| Normal-vs-N1 |
2.21720000026515E-07 |
| N0-vs-N1 |
2.076000E-01 |
|
|
